Captopril monotherapy was associated with no change from baseline in physical symptom distress over 24 weeks, comparing favorably to methyldopa and propranolol which increased specific symptoms.
RCT (n=761)
Does captopril compared to methyldopa or propranolol reduce physical symptom distress in male hypertensive patients?
Captopril is associated with less physical symptom distress compared to methyldopa and propranolol in male hypertensive patients, highlighting its value in preserving quality of life and potentially preventing noncompliance.
We report on the distress associated with physical symptoms in 761 male hypertensive patients enrolled in a clinical trial of the effects of captopril, methyldopa or propranolol on quality of life. Educational level at entry into the trial showed a negative association with a series of physical symptom distress items among patients not previously treated with antihypertensive medications but no association with symptoms among the previously treated. Over the 24 weeks of therapy captopril as monotherapy was associated with no change from baseline in distress in all symptoms examined. In contrast, distress increased in the methyldopa treated patients for dry mouth and blurred vision. Propranolol treated patients had increased "trouble getting breath," bradycardia, shortness of breath or wheezing, and blurred vision. Between group comparisons revealed significant differences favorably comparing captopril to both methyldopa and propranolol in regard to fatigue, and blurred vision, as well as to methyldopa alone for dry mouth and "feeling worn out." There were significant differences as well between captopril and propranolol with patients on propranolol worsening in bradycardia. Other comparisons of patients on propranolol and methyldopa monotherapy showed propranolol patients worsening in bradycardia and loss of taste, but methyldopa patients reported more dry mouth and feeling worn out than those on propranolol. The addition of hydrochlorothiazide to therapy worsened total physical symptom distress scores for methyldopa and propranolol patients. This study confirms the value of methods which assess the degree of distress associated with symptoms commonly reported by hypertensive patients receiving antihypertensive medications. This approach can be useful in establishing a treatment regimen least likely to cause distress and can be of value in preserving quality of life, preventing noncompliance, and withdrawal from treatment.
Schoenberger et al. (Thu,) conducted a rct in Hypertension (n=761). Captopril vs. Methyldopa or propranolol was evaluated on Distress associated with physical symptoms. Captopril monotherapy was associated with no change from baseline in physical symptom distress over 24 weeks, comparing favorably to methyldopa and propranolol which increased specific symptoms.